SU 5214|SU5214|cas 186611-04-1

Cas No.:	186611-04-1
Chemical Name:	SU 5214,SU-5214,SU5214
Synonyms:	SU 5214,SU-5214,SU5214
SMILES:	O=C1NC2=C(C=CC=C2)/C1=C/C3=CC=CC=C3OC
Formula:	C₁₆H₁₃NO₂
M.Wt:	251.28
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has the IC50s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively[1].

Cat. No.	Product name	Field of application
DC70520	JBJ-09-063	JBJ-09-063 is a potent, mutant-selective allosteric EGFR inhibitor against EGFR L858R, T790M and C797S mutations, with IC50 of <0.1 nM for recombinant EGFR L858R/T790M kinase domain.
DC40932	JCN037	JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively.
DC7622	BIBX1382	BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM).
DC12161	TAS6417	TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.
DC10764	Theliatinib (HMPL-309)	Theliatinib (HMPL-309) is a novel small molecule, EGFR tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.
DC5090	WZ4002	WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC9775	WZ3146	WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC10519	SU 5214	SU 5214 is a modulator of tyrosine kinase signal transduction.
DC7078	AZD-8931(Sapitinib)	Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.
DC10479	RX518(CK-101:EGFR-IN-3)	RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations.